[Introductory clinical evaluation of fluticasone propionate efficacy for treatment of allergic rhinitis in children]

Pneumonol Alergol Pol. 1995:63 Suppl 2:83-6.
[Article in Polish]

Abstract

The investigations were carried out on 13 children with seasonal rhinitis, and in 10 children with perennial rhinitis. The fluticasone propionate (Flixonase-Glaxo) was introduced in acute state of disease: one dose to each nostril (100 micrograms) for the patient 7-11 years old, and in the patients under 11 years old--two doses to each nostril (200 micrograms) in the morning, during 3 weeks. The clinical effects were established using score-system in 0-3 points scale which included essential symptoms like: itching, sneezing, nasal blockade, rhinorrhoea, mucosal oedema and eyes irritation. Very good and good effects of the treatment in patients with seasonal rhinitis in 93% of children was observed. In the group of patients with perennial rhinitis, very good and good results, was observed in 80% of children. Easy dosage, high efficacy, very nice smell and no side-effects make this medicine very usefull in the treatment of allergic rhinitis in children.

Publication types

  • Clinical Trial
  • English Abstract

MeSH terms

  • Adolescent
  • Androstadienes / therapeutic use*
  • Anti-Asthmatic Agents / therapeutic use*
  • Child
  • Female
  • Fluticasone
  • Humans
  • Male
  • Rhinitis, Allergic, Perennial / drug therapy*
  • Rhinitis, Allergic, Seasonal / drug therapy*
  • Treatment Outcome

Substances

  • Androstadienes
  • Anti-Asthmatic Agents
  • Fluticasone